ABBOTT LABORATORIES Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
ABBOTT LABORATORIES (ABT) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $24.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-20
- ABBOTT LABORATORIES unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $24.00M, a 27.27% decline from fiscal 2024.
- ABBOTT LABORATORIES unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $33.00M, a 23.26% decline from fiscal 2023.
- ABBOTT LABORATORIES unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $43.00M, a 95.45% increase from fiscal 2022.
- ABBOTT LABORATORIES unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $22.00M, a 43.59% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $24.00M 10-K · filed 2026-02-20 |
| 2024-12-31 | $33.00M 10-K · filed 2026-02-20 |
| 2023-12-31 | $43.00M 10-K · filed 2025-02-21 |
| 2022-12-31 | $22.00M 10-K · filed 2024-02-16 |
| 2021-12-31 | $39.00M 10-K · filed 2023-02-17 |
| 2020-12-31 | $81.00M 10-K · filed 2022-02-18 |
| 2019-12-31 | $8.00M 10-K · filed 2021-02-19 |
| 2018-12-31 | $4.00M 10-K · filed 2020-02-21 |
| 2017-12-31 | $41.00M 10-K · filed 2019-02-22 |
| 2013-12-31 | -$23.00M 10-K · filed 2015-02-27 |
| 2008-12-31 | $20.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |